ContraFect upgraded by WBB Securities with a new price target
$CFRX
Biotechnology: Pharmaceutical Preparations
Health Care
WBB Securities upgraded ContraFect from Speculative Buy to Buy and set a new price target of $6.50
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/14/2022 | $1.00 | Outperform → Mkt Perform | SVB Leerink |
| 7/14/2022 | $15.00 → $1.00 | Overweight → Neutral | Cantor Fitzgerald |
| 2/16/2022 | $14.00 → $9.00 | Outperform | SVB Leerink |
| 2/2/2022 | $6.50 | Speculative Buy → Buy | WBB Securities |
| 9/9/2021 | $14.00 | Outperform | SVB Leerink |
25-NSE - CONTRAFECT Corp (0001478069) (Subject)
8-K - CONTRAFECT Corp (0001478069) (Filer)
10-Q - CONTRAFECT Corp (0001478069) (Filer)
Gainers Intelligent Bio Solutions Inc. (NASDAQ:INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results. Astra Space, Inc. (NASDAQ:ASTR) shares climbed 59.5% to $1.18 after the company announced it received a non-binding proposal from founders Chris Kemp and Adam London offering to acquire all of the outstanding common stock of the company not currently owned by Kemp and London. Tempest Therapeutics, Inc. (NASDAQ:TPST) gained 50% to $4.22 following third-quarter results. Virgin Galactic Holdings, Inc. (NYSE:SPCE) surged 27.5% to $1.99 after the company reported better-than-expected third-quarter financial results. The Honest Company, Inc. (NASDAQ:HNST) gained 23% t
-S-1
Gainers Coherus BioSciences (NASDAQ:CHRS) shares moved upwards by 11.7% to $2.95 during Friday's after-market session. Today's trading volume for this security ended up closing at 1.4 million shares, which is 55.1 percent of its average volume over the last 100 days. The company's market cap stands at $313.8 million. Aligos Therapeutics (NASDAQ:ALGS) stock increased by 11.56% to $0.69. The market value of their outstanding shares is at $30.0 million. ContraFect (NASDAQ:CFRX) shares moved upwards by 11.36% to $0.3. The market value of their outstanding shares is at $1.6 million. ProKidney (NASDAQ:PROK) shares rose 9.61% to $1.65. The market value of their outstanding shares is at $101.6 m
YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that the U.S. Food and Drug Administration (FDA) has notified the company that it has completed the safety review of its Investigational New Drug (IND) application for CF-370 for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), and concluded that the company may proceed with its Phase 1 clinical study. This milestone is significant for ContraFect and historic in the field of
YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Jane Ambler, Ph.D., the Company's Vice President of Clinical Microbiology, will be presenting at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will be held in Boston, MA from September 19-22, 2023. Dr. Ambler's presentation will review the current standards for antimicrobial susceptibility testing (AST) for the determination of antibacterial activity of therap
YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on September 15, 2023. The IND application supports a proposed indication for its intravenous (IV) antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). HABP/VABP are serious, potentially life-threatening infections that are associated with h
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman. Dr. Pomerantz is
Imvax, a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of Josh Muntner as the company's chief financial officer effective August 31, 2021. "We are proud to further bolster our leadership team with the appointment of Josh, who brings to Imvax significant expertise in areas of capital markets and fundraising which will be instrumental to our continued trajectory of growth," said John P. Furey, CEO of Imvax. "I also want to express my profound thanks to Art Howe, co-founder of Imvax and outgoing CFO, for his tireless efforts building the company over the years. We are at a point of exciting momentum as we progress
YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Gary Woodnutt, Ph.D. has been appointed as Senior Vice President of Translational Sciences and Preclinical Development. Dr. Woodnutt will oversee the scientific strategy for the Company's early stage assets and the performance of the extensive translational programs required to proceed into clinical trials. He will have a pivotal role i
SVB Leerink downgraded ContraFect from Outperform to Mkt Perform and set a new price target of $1.00
Cantor Fitzgerald downgraded ContraFect from Overweight to Neutral and set a new price target of $1.00 from $15.00 previously
SVB Leerink reiterated coverage of ContraFect with a rating of Outperform and set a new price target of $9.00 from $14.00 previously
SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)
SC 13G - CONTRAFECT Corp (0001478069) (Subject)
SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)
4 - CONTRAFECT Corp (0001478069) (Issuer)
4 - CONTRAFECT Corp (0001478069) (Issuer)
4 - CONTRAFECT Corp (0001478069) (Issuer)